idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project

idw-News App:


Google Play Store

14.05.2024 13:29

A new precise tool for cardiac research

Christine Vollgraf Presse- und Öffentlichkeitsarbeit
Deutsches Zentrum für Herz-Kreislauf-Forschung e.V.

    An innovative tool for the targeted modification of gene activity in heart muscle cells could establish itself as a standard method for research into cardiovascular diseases. Dr. Patrick Laurette and his colleagues at the German Centre for Cardiovascular Research (DZHK), led by Prof. Ralf Gilsbach, have successfully reduced the activity of individual genes in mouse heart muscle cells using the CRISPRi system. This technology allows for the temporary suppression of gene expression without altering the genetic sequence. It thus avoids the potential risks associated with direct intervention in the genome.

    CRISPRi is based on the CRISPR-Cas genome editing system but lacks the ability to cut DNA, a so-called "dead CAS" (dCAS) and is fused to a KRAB repressor domain. Using a short RNA as a molecular guide dCas9 can bind to specific DNA sequences. As a result, the target region in the genome is epigenetically silenced, and a gene can no longer be read. This blockade is called "epigenetic silencing".

    To introduce the CRISPRi system into the heart muscle cells of mice, the researchers used adeno-associated viruses (AAV), which do not integrate into the genome. One challenge was to package the entire system into the limited genomic capacity of the AAVs. The researchers succeeded in doing this by using a particularly small dCAS. Although other viral vectors have more capacity in this respect, they cannot efficiently reach heart muscle cells or integrate into the genome.

    Effective blockade in the heart muscle

    Dr. Patrick Laurette and his colleagues at Heidelberg University Hospital demonstrated how well epigenetic silencing with the AAV-CRISPRi system works in heart cells for several genes and enhancers. The activity of some genes decreased by up to 95 percent. Enhancers are regulatory elements that can fine-tune gene expression from distant genomic regions.

    "The complexity of the mammalian organism is the result of around one million regulatory elements. There are between fifty and one hundred thousand of these enhancers in heart muscle cells alone," says Prof. Ralf Gilsbach. They are now focusing on modulating these regulatory elements using their new method to treat diseases such as heart failure or cardiac arrhythmia.

    Translational perspective

    Gilsbach emphasizes the translational significance of this approach, which makes it possible to specifically influence gene expression in vivo without changing the DNA sequence. The method is also titratable, meaning it can be regulated and its effect can be reversed. Compared to other methods, such as genetic knock-out, in which genes are destroyed, the AAV-CRISPRi system offers a more precise imitation of natural regulatory mechanisms.

    Methodically optimized and further developed, the procedure could also be used for human therapy in the long term. "I am convinced that this approach has translational significance, even if it is difficult to predict how quickly development will continue here," says Gilsbach.

    There are already numerous companies that are considering AAVs to deliver CRISPR components for therapies. Among other things, they are working on avoiding unwanted antibody reactions. This is because humans have antibodies against AAV and often also against the CRISPR protein derived from bacteria.

    Wissenschaftliche Ansprechpartner:

    Prof. Ralf Gilsbach, Heidelberg University Hospital, Institute of Experimental Cardiology, ralf.gilsbach(at)


    Laurette P, Cao C, Ramanujam D, et al. In Vivo Silencing of Regulatory Elements Using a Single AAV-CRISPRi Vector. Circ Res. 2024;134(2):223-225. doi: 10.1161/CIRCRESAHA.123.323854


    Together with Patrick Laurette, Ralf Gilsbach is investigating how well epigenetic silencing with the AAV-CRISPRi system works in heart cells.
    Together with Patrick Laurette, Ralf Gilsbach is investigating how well epigenetic silencing with th ...


    Patrick Laurette
    Patrick Laurette


    Merkmale dieser Pressemitteilung:
    Journalisten, Studierende, Wissenschaftler
    Biologie, Ernährung / Gesundheit / Pflege, Medizin


    Together with Patrick Laurette, Ralf Gilsbach is investigating how well epigenetic silencing with the AAV-CRISPRi system works in heart cells.

    Zum Download


    Patrick Laurette

    Zum Download



    Die Suche / Erweiterte Suche im idw-Archiv

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.


    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).


    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.


    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).